Whistleblower Law Blog
Four Drug Companies Settle False Claims Act Case for $124 Mil.
On October 19, 2009, the Department of Justice announced that four pharmaceutical manufacturers, Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals, and Ortho McNeil Pharmaceutical settled claims brought against them under the False Claims Act for $124 million. The case alleged that the companies misclassified “innovator” drugs as “non-innovator” drugs and underpaid quarterly rebates owed to state Medicaid programs. The case was brought by Ven-A-Care, a Key West, Florida company who will receive $10,787,392 for their efforts.
A copy of the DoJ press release is available here. For information on The Employment Law Group® law firm’s False Claims Act Practice, please click here.
Tagged: False Claims Act (FCA), Whistleblower Laws (Federal)
The Employment Law Group® law firm produces this blog to provide general news and information about the field of whistleblower law. The blog does not contain any legal advice upon which you should rely or act. Please read our disclaimer.
Editor-in-Chief
R. Scott Oswald
Contributing Editor
Laurence Hooper
Popular Topics
- Administrative Review Board (ARB)
- Dodd-Frank Act
- False Claims Act (FCA)
- Foreign Corrupt Practices Act (FCPA)
- Internal Revenue Service (IRS)
- Medicare Fraud
- Occupational Safety and Health Administration (OSHA)
- Sarbanes-Oxley Act (SOX)
- Securities and Exchange Commission (SEC)
- Securities Fraud
- Tax Fraud
- Title VII of the Civil Rights Act of 1964
- Whistleblower Protection Act (WPA)
